USA flag logo/image

An Official Website of the United States Government

Minimally-Invasive Image-Guided Therapy for Cancer Treatment

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89486
Program Year/Program:
2008 / STTR
Agency Tracking Number:
CA128130
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CONTRADYN, INC.
CONTRADYN, INC. 615 ARAPEEN DR, STE 102 SALT LAKE CITY, UT 84108
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Minimally-Invasive Image-Guided Therapy for Cancer Treatment
Agency: HHS
Contract: 1R41CA128130-01A2
Award Amount: $149,562.00
 

Abstract:

DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a technology and eventually a minimally-invasive commercial system for image-guided photodynamic therapy for cancer. This is certainly in keeping with NCI's focus o n imaging in vivo for cancer screening, diagnosis, progression, image-guide therapy, treatment monitoring, and recurrence. In studies conducted at the University of Utah's Department of Pharmaceutics, Professor Lu's research team has designed and synthesiz ed a bifunctional polymer containing an MRI contrast agent and a photosensitizer, and has demonstrated strong visualization of mouse tumors in MRI with the bifunctional conjugate, and good therapeutic efficacy when tumors were treated photodynamic therapy. ContraDyn, Inc. has licensed the technology which has allowed for this advance. Thus this proposal is a collaborative effort among the University of Utah, the inventor, and ContraDyn, Inc. Building on Professor Lu's work this proposal will incorporate a s pecific targeting agent to reduce the amount of chemicals to which people would be exposed. Challenges still to be met for photodynamic therapy include delivery of sufficient photosensitizer to target tissues, and accurate light-irradiation of the target. An efficient targeted drug-delivery system for both the photosensitizer and imaging probe is the ultimate goal of this program. Specifically, this grant would allow us to 1) design, synthesize, and characterize a tumor-specific targeted, bifunctional polym er; 2) evaluate the efficacy of the targeted, bifunctional polymer for tumor imaging and cancer treatment in a tumor-mouse model at several doses; and 3) optimize the synthesis and analytical methods for the safest formulation of the targeted, bifunctional polymer. PUBLIC HEALTH RELEVANCE: Photodynamic therapy has been shown to be an effective approach for treating cancers which are not accessible to surgery or are resistant to chemotherapy. Currently with photodynamic therapy it is difficult to remove, abl ate, or treat tumor-tissue without harming the surrounding normal tissue. Addition of tumor-targeting agents and improved delivery systems should result in better outcomes and reduced damage to surrounding tissues.

Principal Investigator:

Business Contact:

Small Business Information at Submission:

CONTRADYN, INC.
CONTRADYN, INC. 615 ARAPEEN DR, STE 102 SALT LAKE CITY, UT 84108

EIN/Tax ID: 120504115
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No